Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CCR2 | P41597 | 3/20 | 0.49 |
| ▸ | APOL1 | O14791 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | GPR6 | P46095 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857374 | 1.00 | ALDH1A1 (0.55) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14856469 | 0.90 | ALDH1A1 (0.55) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14856468 | 0.90 | ALDH1A1 (0.55) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14857154 | 0.84 | ALDH1A1 (0.68) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14857155 | 0.84 | ALDH1A1 (0.68) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14856126 | 0.81 | RAB9A (0.69) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14856635 | 0.81 | RAB9A (0.69) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14856205 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL14856372 | 0.80 | RAB9A (0.59) | ALDH1A1KDM4ECRBNRAB9ANPC1 | |
| SCHEMBL31507408 | 0.80 | CRBN (0.78) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-07-04 | — | — | US | claimed |
| EP-2580196-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | claimed |
| WO-2011154696-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | claimed |
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2580196-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154696-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | ALDH1A1 196/4885KDM4E 1765/4885CRBN 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.